Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Bought by 49 Wealth Management LLC

49 Wealth Management LLC lifted its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 81.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,558 shares of the company’s stock after acquiring an additional 10,145 shares during the quarter. 49 Wealth Management LLC’s holdings in Zentalis Pharmaceuticals were worth $83,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. GSA Capital Partners LLP boosted its stake in shares of Zentalis Pharmaceuticals by 138.5% during the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock worth $2,240,000 after acquiring an additional 353,384 shares in the last quarter. Decheng Capital LLC boosted its stake in shares of Zentalis Pharmaceuticals by 46.2% during the 2nd quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock worth $12,558,000 after acquiring an additional 970,859 shares in the last quarter. XTX Topco Ltd boosted its stake in shares of Zentalis Pharmaceuticals by 1,581.9% during the 2nd quarter. XTX Topco Ltd now owns 178,465 shares of the company’s stock worth $730,000 after acquiring an additional 167,854 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Zentalis Pharmaceuticals by 20.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock worth $54,999,000 after acquiring an additional 585,644 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Zentalis Pharmaceuticals by 152.6% during the 2nd quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock worth $2,706,000 after acquiring an additional 399,745 shares in the last quarter.

Zentalis Pharmaceuticals Trading Up 1.6 %

ZNTL opened at $3.23 on Friday. The stock has a market cap of $230.17 million, a price-to-earnings ratio of -1.30 and a beta of 1.74. Zentalis Pharmaceuticals, Inc. has a 1 year low of $2.66 and a 1 year high of $18.07. The stock has a fifty day moving average price of $3.42 and a 200 day moving average price of $5.18.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. As a group, sell-side analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on ZNTL. Wedbush raised Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price objective for the company in a research note on Monday, August 12th. Oppenheimer reaffirmed an “outperform” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th. Guggenheim decreased their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, November 15th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Zentalis Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.